Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
| ▸ | LDHA | P00338 | 1/20 | 0.63 |
| ▸ | PPARG | P37231 | 1/20 | 0.61 |
| ▸ | PPARA | Q07869 | 1/20 | 0.61 |
| ▸ | MMP2 | P08253 | 1/20 | 0.58 |
| ▸ | MMP9 | P14780 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.55 |
| ▸ | ACE | P12821 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | MMP3 | P08254 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1702385 | 0.89 | FPR2 (0.55) | FPR2KMT2ALDHAPPARGPPARA | |
| SCHEMBL29228692 | 0.87 | FPR2 (0.62) | FPR2KMT2ALDHAPPARGPPARA | |
| SCHEMBL30872672 | 0.87 | FPR2 (0.62) | FPR2KMT2ALDHAPPARGPPARA | |
| SCHEMBL30915498 | 0.86 | PLAU (0.60) | FPR2KMT2APPARGPPARAMMP2 | |
| SCHEMBL5189503 | 0.85 | FPR2 (0.68) | FPR2KMT2ALDHAALDH1A1ALOX15 | |
| SCHEMBL28946718 | 0.85 | FPR2 (0.71) | FPR2KMT2ALDHAPPARGPPARA | |
| SCHEMBL28946720 | 0.85 | FPR2 (0.71) | FPR2KMT2ALDHAPPARGPPARA | |
| SCHEMBL12157350 | 0.85 | FPR2 (0.64) | FPR2KMT2ALDHAPPARGPPARA | |
| SCHEMBL157547 | 0.85 | MME (0.61) | MMP2MMP9ACE | |
| SCHEMBL7751730 | 0.84 | LDHA (0.67) | FPR2KMT2ALDHAPPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12023316-B2 | FAP-activated therapeutic agents, and uses related thereto | BACH BIOSCIENCES, LLC (US) | 2024-07-02 | — | — | US | disclosed |
| CN-118201628-A | Transmembrane peptide antagonists of plexin A1 and therapeutic uses thereof | 斯特拉斯堡大学 | 2024-06-14 | — | — | CN | disclosed |
| WO-2024103178-A1 | ANISOMYCIN ANALOGS AND USES THEREOF | Université de Montréal (CA) | 2024-05-23 | — | — | WO | disclosed |
| WO-2024050627-A1 | CSGA-DERIVED NANOSTRUCTURES AND USES THEREOF FOR ANTIGEN DELIVERY | BOURGAULT STEVE (CA) | 2024-03-14 | — | — | WO | disclosed |
| US-11925655-B2 | FAP-activated therapeutic agents, and uses related thereto | BACH BIOSCIENCES, LLC (US) | 2024-03-12 | — | — | US | disclosed |
| EP-4299134-A2 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | Bach Biosciences, LLC (US) | 2024-01-03 | — | — | EP | disclosed |
| EP-4219767-A1 | PAPD5 AND PAPD7 INHIBITORS FOR TREATING A HEPATITIS B INFECTION | F. Hoffmann-La Roche AG (CH) | 2023-08-02 | — | — | EP | disclosed |
| US-20230234991-A1 | SELF-ASSEMBLED PEPTIDE NANORODS AND USES THEREOF | TRANSFERT PLUS SOC EN COMMANDITE (CA) | 2023-07-27 | — | — | US | disclosed |
| EP-3154594-B1 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | BACH BIOSCIENCES LLC (US) | 2023-07-19 | — | — | EP | disclosed |
| CN-116196411-A | PAPD5 and PAPD7 inhibitors for the treatment of hepatitis B infection | 豪夫迈·罗氏有限公司 | 2023-06-02 | — | — | CN | disclosed |
| EP-1511764-A2 | PEPTIDES AND PEPTIDOMIMETICS USEFUL FOR INHIBITING THE ACTIVITY OF PROSTAGLANDIN F sb 2a /sb RECEPTOR | THERATECHNOLOGIES INC. (CA) | 2005-03-09 | — | — | EP | disclosed |
| US-6864239-B2 | Methods and compounds for prevention and treatment of elevated intraocular pressure and related conditions | THERATECHNOLOGIES INC. (CA) | 2005-03-08 | — | — | US | disclosed |
| WO-2004113513-A2 | METHODS AND COMPOSITIONS FOR MODULATING STEM CELL GROWTH AND DIFFERENTIATION | OTTAWA HEALTH RESEARCH INSTITUTE (CA) | 2004-12-29 | — | — | WO | disclosed |
| WO-2004111078-A2 | COMPOUNDS THAT MODULATE THE GLUCAGON RESPONSE AND USES THEREOF | THERATECHNOLOGIES INC. (CA) | 2004-12-23 | — | — | WO | disclosed |
| EP-1487872-A1 | METHODS AND COMPOUNDS FOR PREVENTION AND TREATMENT OF ELEVATED INTRAOCULAR PRESSURE AND RELATED CONDITIONS | THERATECHNOLOGIES INC. (CA) | 2004-12-22 | — | — | EP | disclosed |
| US-20040235749-A1 | G-protein coupled receptor antagonists | HOPITAL SAINTE-JUSTINE (CA) | 2004-11-25 | — | — | US | disclosed |
| US-20040023853-A1 | Antagonistic peptides of prostaglandin E2 receptor subtype EP4 | THERATECHNOLOGIES INC. (CA) | 2004-02-05 | — | — | US | disclosed |
| WO-2003104266-A2 | PEPTIDES AND PEPTIDOMIMETICS USEFUL FOR INHIBITING THE ACTIVITY OF PROSTAGLANDIN F2α RECEPTOR | THERATECHNOLOGIES INC. (CA) | 2003-12-18 | — | — | WO | disclosed |
| US-20030212001-A1 | Methods and compounds for prevention and treatment of elevated intraocular pressure and related conditions | THERATECHNOLOGIES INC. (CA) | 2003-11-13 | — | — | US | disclosed |
| WO-2003080659-A1 | METHODS AND COMPOUNDS FOR PREVENTION AND TREATMENT OF ELEVATED INTRAOCULAR PRESSURE AND RELATED CONDITIONS | THERATECHNOLOGIES INC. (CA) | 2003-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12023316-B2 | FAP-activated therapeutic agents, and uses related thereto | FAP, FIBP, GOT1 | FPR2 1276/4885KMT2A 3355/4885LDHA 1001/4885 |
| US-20040023853-A1 | Antagonistic peptides of prostaglandin E2 receptor subtype EP4 | PTGER4, PTGER1, PTGFR | FPR2 165/4885KMT2A 3258/4885LDHA 3823/4885 |
| US-11925655-B2 | FAP-activated therapeutic agents, and uses related thereto | FAP, FIBP, GOT1 | FPR2 1760/4885KMT2A 3066/4885LDHA 724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.